Compare Mongodb Inc (MDB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs TG Therapeutics Inc — how do they compare? Mongodb Inc trades at $386 (market cap $29.24B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: Mongodb Inc is far larger — about 3.6× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 46 Days and TG Therapeutics Inc for 16 Days on average.
| MDB | TGTX | |
|---|---|---|
Market Cap | $29.24B | $8.16B |
Volume | 1,304,995 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $472.29 | $59.06 |
52-Week Low | $225.95 | $26.94 |
Typical Hold Time | 46 Days | 16 Days |
Enterprise Value | $26.86B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDB trades at $383.26, up 5.57% today, with a bullish technical signal and strong analyst support. The stock is near resistance at $384 after recent volatility from a CEO transition. Fundamentally, revenue growth is robust, reaching $2.01B in 2025, but profitability remains negative with a net loss of $129M. Recent Investor Day highlighted AI product launches and raised long-term targets, fueling optimism.
Outlook is positive with 80% analyst buy ratings and a $456.76 consensus target, but risks include persistent losses, high valuation multiples, and execution challenges amid leadership changes. The stock offers growth exposure to AI-driven database demand, yet investors must weigh profitability concerns against expansion potential.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
